此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Neurobiological Bases of Paternal Nurturance

2017年4月27日 更新者:James K. Rilling, PhD

Biological Bases of Individual Variation in Paternal Nurturance

The overall goal of this project is to identify the genetic, hormonal, and neurobiological influences on paternal nurturing behavior and to determine if fathers' neural responses to infants can be modulated by neuropeptides known to play a role in parenting in experimental animal models.

The aim is to determine if pharmacological manipulation of central oxytocin (OT) and vasopressin (AVP) levels influences the neural response to viewing pictures of one's own infant or to hearing cry stimuli. In a double-blind procedure, fathers with 1-3 year old children will be scanned on two separate occasions; once under the influence of OT/AVP and once under the influence of placebo. Fathers will be randomized to either OT or AVP, and order of administration of drug and placebo will counterbalanced across subjects. Fathers will be scanned while viewing pictures of their own and an unknown child and while listening to unknown infant cry stimuli.

The investigators hypothesize:

  • OT will augment the ventral tegmental area (VTA), ventral striatum and medial orbitofrontal cortex (mOFC) response to viewing pictures of one's own child, and will augment the primary auditory cortex (AI) response of fathers to infant cries.
  • AVP will augment the lateral septum response to viewing own child pictures.

研究概览

详细说明

30 fathers of children aged 1-3 will participate in two functional imaging sequence (fMRI) sessions, once under the influence of OT/AVP, and once under the influence of placebo. Fathers will be restricted to men who are living with their biological child and an adult partner (male or female) that they are in a committed relationship with. All fathers will receive two fMRI scans on two different occasions, separated by 2-10 days. 15 fathers will be randomized to intranasal OT, the other 15 will be randomized to intranasal AVP. Within each drug group, the order of administration of drug and placebo will counterbalanced across subjects, such that 15 will receive OT/AVP first, and 15 will receive OT/AVP second. During the fMRI scans, fathers will view pictures of their own and unknown children, as well as unknown adults. Afterwards, while still in the scanner, they will listen to infant cry and control stimuli. After exiting the scanner, fathers will again listen to the cry stimuli and will rate their emotional reaction to the cry stimuli on the following dimensions using a 7 point likert scale: irritated, sympathetic, alarmed, angry, upset, compassionate, distressed, annoyed, and tender.

研究类型

介入性

注册 (实际的)

35

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Georgia
      • Atlanta、Georgia、美国、30307
        • Emory University Hospital
      • Atlanta、Georgia、美国、30322
        • Emory University 1462 Clifton Rd

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • above 18
  • biological fathers of 1-3 year old infants who are currently cohabitating with the child's mother
  • normal or corrected-to-normal vision of 20/40

Exclusion Criteria:

  • current or past history of mental illness
  • active medical or neurological disorder
  • current or past history of alcohol or drug dependence
  • claustrophobic (at the discretion of the PI with subject consultation)
  • history of seizures or other neurological disorder
  • history of hypertension, cardiovascular disease, nephritis, diabetes or other endocrine diseases or malignancy
  • ferrous metal in any part of the body
  • history of asthma or migraine headaches (can be included at the discretion of the study physician or nurse practitioner if episodes are infrequent and no active problems at time of study, not medicated)
  • history of head trauma or psychiatric illness, as well as those who are receiving or have received over the past year, medication with known psychoactive effects (included at the discretion of the PI as these are exclusion criteria due to data quality concerns and not safety concerns; head trauma should be minimal enough deemed by the PI)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:随机化
  • 介入模型:交叉作业
  • 屏蔽:三倍

武器和干预

参与者组/臂
干预/治疗
实验性的:OT + placebo
The OT + placebo group will self-administer no more than 1 ml solution of oxytocin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive OT first, and half will receive OT second.
1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
其他名称:
  • 催产素
  • 加时赛
1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
实验性的:AVP + placebo
The AVP + placebo group will self-administer no more than 1 ml solution of vasopressin or placebo in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays. The order of administration of drug and placebo will counterbalanced across subjects, such that half will receive AVP first, and half will receive AVP second.
1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
其他名称:
  • 降压素
  • Arginine vasopressin (AVP)
  • Antidiuretic hormone (ADH)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Mean Percent Signal Change in Ventral Tegmental Area (VTA)
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol.
Baseline, Visit 2 (Up to 10 days)
Mean Percent Signal Change in Right Ventral Striatum
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol.
Baseline, Visit 2 (Up to 10 days)
Mean Percent Signal Change in Right Medial Orbitofrontal Cortex
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol.
Baseline, Visit 2 (Up to 10 days)
Mean Percent Signal Change in Caudate Nucleus
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI).
Baseline, Visit 2 (Up to 10 days)
Mean Percent Signal Change in the Visual Cortex
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI).
Baseline, Visit 2 (Up to 10 days)
Mean Percent Signal Change in the Anterior Cingulate Cortex
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI).
Baseline, Visit 2 (Up to 10 days)

次要结果测量

结果测量
措施说明
大体时间
Change in Plasma Levels of Vasopressin (AVP)
大体时间:Baseline, Visit 2 (Up to 10 days)
Peripheral levels of AVP will be assessed via assay of plasma collected.
Baseline, Visit 2 (Up to 10 days)
Change in Plasma Levels of Oxytocin (OT)
大体时间:Baseline, Visit 2 (Up to 10 days)
Peripheral levels of OT will be assessed via assay of plasma collected.
Baseline, Visit 2 (Up to 10 days)
Difference in Cry Rating Scores Between OT and Placebo
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by analyzing the differences between ratings of infant cries under OT and placebo treatment on a 7-point likert scale. Sixteen adjectives will be used to describe two different cries. Participants will rate each cry from 1-7 where one represents "not at all" and 7 represents "extremely". Difference is defined as OT minus placebo scores.
Baseline, Visit 2 (Up to 10 days)
Difference in Cry Rating Scores Between AVP and Placebo
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by analyzing the differences between ratings of infant cries under AVP and placebo treatment on a 7-point likert scale. Sixteen adjectives will be used to describe two different cries. Participants will rate each cry from 1-7 where one represents "not at all" and 7 represents "extremely". Difference is defined as AVP minus placebo scores.
Baseline, Visit 2 (Up to 10 days)
Mean Percent Signal Change in Primary Auditory Cortex
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between OT treatment and placebo treatments (OT-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the OT group only per protocol.
Baseline, Visit 2 (Up to 10 days)
Mean Percent Signal Change in Right Lateral Septum
大体时间:Baseline, Visit 2 (Up to 10 days)
The effect of the drug will be assessed by determining changes in brain activation to own child pictures versus adult pictures (O-A) between AVP treatment and placebo treatments (AVP-PL) from functional magnetic resonance imaging (fMRI). Changes will be assessed in the AVP group only per protocol.
Baseline, Visit 2 (Up to 10 days)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:James K Rilling, Ph.D.、Emory University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2014年8月1日

初级完成 (实际的)

2016年2月1日

研究完成 (实际的)

2016年2月1日

研究注册日期

首次提交

2014年8月20日

首先提交符合 QC 标准的

2014年8月20日

首次发布 (估计)

2014年8月22日

研究记录更新

最后更新发布 (实际的)

2017年6月5日

上次提交的符合 QC 标准的更新

2017年4月27日

最后验证

2017年4月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅